ESG data

Governance

*The numbers of the Astellas Pharma, Inc. Board of Directors are as of the end of each fiscal year.

    Unit FY 2022 FY 2023 FY 2024
Board of Directors structure Board of Directors Persons 10 11 11
Of which Outside Directors Persons 7 7 7
Ratio of Outside Directors % 70 64 64
Of which Female Directors Persons 5 5 5
Ratio of Female Directors % 30 27 45

Number in meetings of 
the Board of Directors

Number 14 13 14

Average Rate of Outside 
Directors’ attendance in 
meetings of the Board of 
Directors

% 98 99 98
Audit & Supervisory
Committee structure
Audit & Supervisory
Committee Members
Persons 4 4 4
Of which Outside
Directors 
Persons 3 3 3
Of which Female Directors Persons 2 2 4
Number in meetings of the
Audit & Supervisory 
Committee
Number 19 20 20
Average Rate of Outside 
Director’s attendance in 
meetings of the Audit & 
Supervisory Committee
% 100 100 100
Nomination Committee structure Chair   Outside Director Outside Director Outside Director
Member of the
Nomination Committee
(including Chair)
Persons 4 4 4
Of which Outside
Directors
Persons 4 4 4
Number in meetings of the 
Nomination Committee
Number 7 9 9

Average Rate of Outside 
Director’s attendance in
meetings of the 
Nomination Committee

% 100 97 97
Compensation Committee structure Chair   Outside Director Outside Director Outside Director
Member of the
Compensation Committee
(including Chair)
Persons 4 4 4
Of which Outside
Directors
Persons 4 4 4
Number in meetings of the 
Compensation Committee
Number 7 7 10

Average Rate of Outside 
Director’s attendance in 
meetings of the 
Compensation Committee

% 100 100 100

Number of Substantiated Breaches (Disclosed since FY2023)

Reporting Areas Unit FY2023
Corruption or Bribery Matters 0
Conflicts of Interest Matters 2
Money Laundering or Insider Trading Matters 1
Discrimination or Power Harassment* Matters 4

  • *This includes matters that were reported to E&C and investigated to conclusion through the global investigation process led by E&C and Legal. It does not include issues reported directly to other departments or which E&C referred to another department to handle as it deemed appropriate